Regenxbio Inc (NAS:RGNX)
$ 7.41 -0.46 (-5.84%) Market Cap: 367.13 Mil Enterprise Value: 218.52 Mil PE Ratio: 0 PB Ratio: 1.22 GF Score: 65/100

Regenxbio Inc at RBC Capital Markets Global Healthcare Conference Transcript

May 16, 2023 / 07:35PM GMT
Release Date Price: $19.72 (-9.17%)
Luca Issi
RBC Capital Markets - Analyst

Thanks. Hello, everybody. I'm Luca Issi, a senior biotech analyst here at RBC Capital Markets. And today, it's a great privilege to have REGENXBIO with us for a fireside chat. Representing the company, we have Ram Palanki, Executive Vice President of Commercial Strategy and Operation.

Ram, thanks again for joining us. How are you doing today?

Ram Palanki
REGENXBIO Inc. - EVP, Commercial Strategy & Operations

I'm good, man. How are you?

Questions & Answers

Luca Issi
RBC Capital Markets - Analyst

Good. Good, good, good. We have a long list of questions here. But maybe before we ask you about the individual program, it would be just great if you could give us a little bit of a big-picture overview of what progress has the organization made over the last few months? And then, most importantly, what's ahead here for REGENXBIO?

Ram Palanki
REGENXBIO Inc. - EVP, Commercial Strategy & Operations

Yeah. Thanks

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot